Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020
Adaptive Biotechnologies (Nasdaq: ADPT) will release its third-quarter financial results on November 10, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will release its third-quarter financial results on November 10, 2020, after market close. The company will host a conference call at 1:30 p.m. PT, with a webcast available via the Investors section of its website. Adaptive focuses on leveraging the adaptive immune system's genetics to develop clinical diagnostics and therapeutics, aiming to address diseases like cancer and autoimmune conditions. The firm currently has two commercial products and an expansive clinical pipeline.
Positive
- Adaptive has two commercial products and a robust clinical pipeline for addressing cancer and autoimmune diseases.
Negative
- None.
Details
News Market Reaction – ADPT
The recorded move for ADPT in the trading session of this news was -2.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter ended September 30, 2020 after market close on Tuesday, November 10, 2020. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.